Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

NPY receptor antagonists with dihydropyridine structure disclosed by Bristol-Myers Squibb

Jan. 6, 2000

AstraZeneca explores novel strategy for treating diabetes and certain other disorders

Jan. 6, 2000

Apo A-IV peptide suppresses appetite in obese rats, offered for licensing

Jan. 6, 2000

Tibolone improves auditory function in postmenopausal women

Jan. 6, 2000

AstraZeneca presents new series of insulin sensitizers

Jan. 5, 2000

G-CSF mimetics discovered at SB and claimed for neutropenia and infections

Jan. 4, 2000

Levotech completes phase IIb study of seven-day contraceptive patch

Jan. 3, 2000

Phase II study of Fabry's disease treatment successfully completed

Jan. 3, 2000

Expanded patent protection for Theratechnologies' GRF analogue program

Dec. 30, 1999

Crinone associated with reduced implantation, pregnancy rates following IVF-ET

Dec. 30, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...